Document:

<PAGE>

                                                                 EXHIBIT 10.17.2

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

June 30, 2003

Mr. Kevin Corcoran
President and Chief Executive Officer
Lynx Therapeutics, Inc.
25861 Industrial Blvd.
Hayward, CA 94545, USA

         Re: Amendment No. 2 to Collaboration Agreement

Dear Mr. Corcoran:

         This letter (the "Second Amendment") shall be effective on [ * ], 2003
("Effective Date") and will serve to confirm and memorialize our agreement to
amend, in certain respects, that certain Collaboration Agreement (the
"Collaboration Agreement"), effective as of October 1, 2000 between Takara Bio,
Inc. ("Takara Bio"), as successor-in-interest to Takara Shuzo Co., Ltd., and
Lynx Therapeutics, Inc. ("Lynx")(as amended by that certain Amendment No. 1 to
Collaboration Agreement, dated December 19, 2002 (the "First Amendment")).
Please note that all terms used herein, which are not otherwise defined, shall
be given the definition ascribed to such term in the Collaboration Agreement.

         1.       Lynx hereby grants to Takara Bio an exclusive, fully paid-up,
non-transferable, irrevocable, perpetual, royalty-free license to all of the
patents, technology and software which Lynx owns in the Territory relevant to
Megaclone(TM), Megasort(TM), and MPSS(TM), and all of the Lynx technology and
know-how listed in Exhibit 1 of the Collaboration Agreement for the purpose of
providing MPSS(TM) and Megasort(TM) services to customers in the Territory and
to permit Takara Bio to make or have made, import or distribute and sell
Microarrays containing nucleic acid sequences identified by Megasort(TM) or
MPSS(TM) technologies to customers in the Territory; all as more particularly
set forth on [ * ]. Lynx shall use its reasonable efforts to prosecute and
maintain such patents, and to transfer all current PCT applications to each
country

<PAGE>

comprising the Territory at Lynx' expense and for no additional consideration.
In the event that Lynx or any current or successor entity is unable to maintain
such patents and patent applications in the Territory, Lynx shall take or cause
to be taken all steps necessary to transfer to Takara Bio (or its designated
affiliate) all right, title and interest in and to these patents and patent
applications in the Territory. All language in the Collaboration Agreement,
which is contrary to or inconsistent with the rights granted in this paragraph,
is hereby deemed deleted.

         2.       Lynx agrees to provide Takara Bio, [ * ], with a total of [ *
] weeks of training and instruction in the use of the technology and know-how
related to the [ * ] on mutually agreeable dates in Hayward, California to
enable Takara Bio to [ * ]; provided that Takara Bio shall be responsible for
related travel and lodging costs incurred by Takara Bio in connection with the
training and instruction provided hereunder. In addition, Lynx agrees to provide
Takara Bio and Takara Bio is required to obtain directly from Lynx, on a first
priority basis after satisfying Lynx's internal needs, with the [ * ] necessary
for the [ * ] upon mutually agreed upon terms and conditions, which shall, in no
event, be less favorable than those accorded to any other commercial customers
of Lynx. In the event that Lynx is unable, for any reason whatsoever, to supply
such [ * ] to Takara Bio, Lynx shall, at its own expense, assist Takara in
arranging for a supply of the [ * ] from an alternate source, which is
reasonably acceptable to Takara Bio.

         3.       Lynx, as of the Effective Date of this Second Amendment,
hereby waives and releases Takara Bio from (i) the payment of the technology
access fee in the amount of US$1 million otherwise payable by Takara Bio on [ *
], 2003 pursuant to paragraph 4(b) of the First Amendment, (ii) the equity
investment in the amount of US$1 million which Takara Bio would otherwise be
required to make on [ * ], 2003 pursuant to paragraph 5(b) of the First
Amendment, (iii) the payment of the technology access fee in the amount of US$1
million otherwise payable by Takara Bio on [ * ], 2004 pursuant to paragraph
4(c) of the First Amendment, (iv) the equity investment in the amount of US$1
million which Takara Bio would otherwise be required to make on [ * ], 2004
pursuant to paragraph 5(c) of the First Amendment and (v) payment of the running
royalties which Takara Bio would otherwise be obligated to make pursuant to
Article

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       2

<PAGE>

9.1(a) and (b) of the Collaboration Agreement for the remainder of the term of
the Collaboration Agreement.

         4.       Lynx shall provide Takara Bio with three [ * ] instruments for
MPSS analysis within [ * ] of the Effective Date of this Second Amendment.

         5.       Within [ * ] after the Effective Date, Lynx shall file a
registration statement under the Securities Act of 1933, as amended ("Securities
Act"), and use its best efforts to cause such registration statement to be
declared effective by the Securities and Exchange Commission as promptly
thereafter as is practicable to permit or facilitate the sale and distribution
of [ * ] Takara Bio's shares of Lynx common stock on a continuous basis pursuant
to Rule 415 under the Securities Act. No other shares of Lynx common stock or
other securities shall be included in such registration, whether held by other
stockholders or newly-issued by Lynx, without the prior written consent of
Takara Bio. Lynx shall, subject to applicable law or applicable interpretations
of the staff of the SEC, use its best efforts to keep the registration statement
continuously effective until two years after the last purchase of shares of Lynx
common stock by Takara Bio or such shorter period ending when (i) all shares of
Lynx common stock covered by the registration statement have been sold by Takara
Bio or otherwise cease to be outstanding or (ii) all such shares are eligible to
be sold pursuant to Rule 144(k) under the Securities Act and Lynx has complied
with all requirements that would permit such sale under Rule 144(k). Lynx shall
pay for all expenses incurred in connection with the registration including,
without limitation, all filing, registration and qualification fees, printing
expenses, and Lynx' legal and accounting fees. Takara Bio shall pay for all
expenses related to underwriting discounts and selling commissions, if any, in
connection with the sale of any shares of Lynx common stock by Takara Bio under
the registration statement.

         6.       In consideration of the rights granted herein, Takara Bio
agrees to make a payment of US$3 million to Lynx no later than [ * ] following
the Effective Date of this Second Amendment.

         If the foregoing is consistent with Lynx' understanding of our
agreement,

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       3

<PAGE>

please execute the enclosed copy of this letter and return it to Takara Bio.

                                                 Very truly yours,

                                                 /s/ Ikunoshin Kato
                                                 -------------------------------
                                                 Ikunoshin Kato
                                                 President and C.E.O.
                                                 Takara Bio, Inc.

Confirmed and agreed to: Lynx Therapeutics, Inc.

By: /s/ Kevin P. Corcoran
    -------------------------------------
Kevin P. Corcoran
President & CEO
Lynx Therapeutics, Inc.

[ * ]

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       4<PAGE>

                                                                   EXHIBIT 10.41

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                                             CONFIDENTIAL

                               SERVICES AGREEMENT

         This SERVICES AGREEMENT ("Agreement") is made and entered into as of
[*] 2003 ("Effective Date"), by and between E.I. du Pont de Nemours and Company,
having a principal business address at 1007 Market Street, Wilmington, Delaware
19898 ("DuPont") and LYNX THERAPEUTICS, INC. having a principal business address
at 25861 Industrial Boulevard, Hayward, California, 94545 ("Lynx"). DuPont and
Lynx may be referred to herein collectively as the "Parties" or individually as
a "Party."

         WHEREAS, Lynx has expertise and intellectual property involving the use
of certain molecular biological methods for cloning and identifying the sequence
of nucleic acids, and using such technologies for discovery and characterization
of genes;

         WHEREAS, DuPont and its agricultural Affiliates, including Pioneer
Hi-Bred International, Inc. of Des Moines, Iowa ("Pioneer"), have expertise and
interest in discovering, developing, distributing and marketing agricultural
products and processes;

         WHEREAS, DuPont and Lynx have previously entered into a Research
Collaboration Agreement dated [*] 1998 and subsequently amended from time to
time by the Parties ("1998 Collaboration Agreement") under which Lynx technology
has been applied to[*] analysis of certain crop plants for the benefit of
DuPont's agricultural research and development programs;

         WHEREAS, the Collaboration Agreement is due to expire on [*] 2003; and

         WHEREAS, the Parties desire to continue their interaction with one
another under new terms and conditions.

         NOW, THEREFORE, for good and valuable consideration, the receipt and
sufficiency of which is hereby acknowledged, the Parties agree as follows:

1. Definitions:

   a.    "Affiliate" shall mean any corporation, firm, limited liability
         company, partnership, or other entity that directly or indirectly
         controls, or is controlled by, or is under common control with a Party
         to this Agreement. For the purpose of this definition, control means
         ownership, directly or through one or more Affiliates, of fifty percent
         (50%) (or such lesser percentage which is the maximum allowed to be
         owned by a foreign entity in a particular jurisdiction) or more of the
         shares of stock entitled to vote for the election of directors in the
         case of a corporation, or fifty percent (50%) (or such lesser
         percentage which is the maximum allowed to be owned by a foreign entity
         in a particular jurisdiction) or more of the equity interests in the
         case of any other type of legal entity, or status as a general partner
         in any partnership, or any other arrangement whereby a Party controls
         or has the right to control the board of directors or equivalent
         governing body of a corporation or other entity. For purposes of this
         Agreement, Affiliates shall also include Affiliates of Pioneer.

                                  Page 1 of 12

<PAGE>

                                                             CONFIDENTIAL

   b.    "Results" shall mean all information and materials provided to DuPont
         and its Affiliates by Lynx, or developed by Lynx, under this Agreement,
         including but not limited to all information and materials, including
         datasets, related to the signature tags generated through the use of
         Lynx Technology on Samples, as further described in the Work Plan.

   c.    "Exclusive Plants" shall mean [*].

   d.    "Analysis" shall mean the application of Lynx Technology to a single
         Sample, as further described in the Work Plan.

   e.    "Intellectual Property" shall mean any right that protects any
         invention, improvement or discovery, that is created or discovered
         prior to, during, or as a result of the Services hereunder, whether or
         not patentable, and shall include, but is not limited to, patent
         rights, plant variety protection certificates, patent applications,
         copyrights, trademarks, and trade secrets.

   f.    "Lynx Technology" shall mean any and all technologies owned or
         controlled by Lynx, including but not limited to solid phase cloning of
         nucleic acids on beads and its applications such as Megaclone and
         Massively Parallel Signature Sequencing, ("MPSS").

   g.    "MPSS [*]" shall mean a form of MPSS whereby each resulting sequence
         tag is at least [*] and [*] high quality sequence tags are generated
         from a Sample. This and all forms of MPSS that may be used under this
         Agreement, including "[*]", "[*]", and the like, are further described
         in the Work Plan.

   h.    "Non-exclusive Plants" shall mean all plant species other than
         Exclusive Plants, except for [*].

   i.    "Sample" shall mean the biological material and information provided by
         DuPont under this Agreement for use in an Analysis.

   j.    "Services" shall mean the application by Lynx of Lynx Technology to
         Analyses involving DuPont's Samples, to generate and deliver Results to
         DuPont and its Affiliates.

   k.    "Work Plan" shall mean the detailed description of the Analyses and
         Services to be conducted under this Agreement, including specifications
         regarding Samples and Results, timing of the Analyses and technical
         milestones for the Services and Results, attached as Schedule A herein.

   l.    "Year" shall mean a single calendar year (January 1 through December
         31) during the Term of this Agreement.

2. Scope and Description of Services. Lynx shall conduct the Services for
      DuPont, including its Affiliates, for the Exclusive Plants and
      Non-exclusive Plants using DuPont's Samples and

                                  Page 2 of 12

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

<PAGE>

                                                             CONFIDENTIAL

      according to specifications in the attached Work Plan, or such other
      written schedules, work plans or descriptions that the Parties may agree
      upon from time to time and shall make part of this Agreement.

      Lynx hereby agrees (a) to use Samples solely to perform the Services for
      DuPont and meet its obligations under this Agreement, and (b) to send all
      residual Samples to DuPont (or another site designated by DuPont) within
      [*] calendar days after the date of completion of Services for such
      Samples, or at the end of the Term, or at Termination of this Agreement.
      In the event that DuPont provides written direction to Lynx to destroy all
      residual Samples, Lynx shall do so promptly.

      Lynx shall not distribute, release, sell, disclose, or otherwise transfer
      the Samples to, or use Samples with or on behalf of, any third party,
      except to such affiliates of Lynx as may be necessary for the performance
      of the Services. In such event, Lynx shall notify DuPont of such transfer
      or disclosure, and such Lynx affiliates shall be bound by the same terms
      as contained herein regarding use and treatment of DuPont Samples. DuPont
      agrees to pay directly, or to reimburse Lynx for, any shipping, handling
      or other like expenses that may be incurred in providing Samples to Lynx
      hereunder.

      As consistent with the [*] Analyses forecast and planning provisions
      described in the Work Plan, Pioneer shall provide its Samples to Lynx
      within [*] as necessary for Lynx to conduct the Services in that [*]. Lynx
      shall provide, at its own expense, all equipment, materials, information,
      know-how, and related services as are necessary to perform the Services
      and satisfy its obligations under this Agreement. Lynx shall promptly
      deliver all Results to DuPont upon completion of the corresponding
      Analyses.

3. Exclusive Period. Lynx shall not perform services utilizing Lynx Technology
      to any third party in, or using, the Exclusive Plants ("Exclusive Period")
      (a) during the Term of this Agreement; or (b) if this Agreement is
      terminated as provided in Section 5 herein, for a period of [*] from the
      date of Termination. Lynx may perform services during the Exclusive Period
      to third parties in, or using, the Non-exclusive Plants. DuPont shall be
      granted non-exclusive access to Services with [*], and any other plant
      that may be under exclusive obligations by Lynx to a third party, as soon
      as such access becomes available. Nothing in this Section 3 shall restrict
      Lynx in any way from being able to perform its obligations under any
      agreement in effect prior to the effective date of the 1998 Collaboration
      Agreement for the Exclusive Plants, and prior to the Effective Date of
      this Services Agreement for the Non-exclusive Plants, whether or not such
      performance would otherwise be in violation of this Section 3.

4. Fees and Payments. As further described in the Work Plan, each Year's
      Services, including the type(s), number and unit-cost of Analyses for that
      Year will be discussed and agreed by the Parties in the [*] of the
      previous Year; however, for [*] (Year 1), the Parties hereby agree that
      Lynx shall perform [*] MPSS [*] Analyses for DuPont at a cost of [*] per
      MPSS Signature Analysis. The unit-cost for MPSS [*] Analyses in Years
      subsequent to [*] shall be no more than [*], and shall be no greater than
      [*].

                                  Page 3 of 12

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

<PAGE>

                                                             CONFIDENTIAL

               As full consideration for the Services to be conducted and the
               Results to be delivered to DuPont hereunder, DuPont shall pay
               Lynx the amounts defined in the Payment Schedule below. Beginning
               [*], all payments shall be made by DuPont [*] for the design and
               performance of the Services for the Analyses forecasted by the
               Parties and the work to be conducted [*]. DuPont shall [*] to
               make all payments under this Agreement.

               Payment Schedule. Subject to Section 5, DuPont shall pay Lynx the
               following total amounts for the Services to be performed in the
               respective Year under this Agreement:

               Year 1 ("Year 1"; [*]): [*] Dollars (USD $[*]), payable by DuPont
               as:

                           (a)      [*] Dollars (USD $[*]) due upon [*], for the
                               Services to be performed by Lynx in Year 1; and

                           (b)      [*] payments of [*] Dollars (USD $[*]) [*]
                               due on or before the [*]) day of [*] and [*],
                               respectively, for the Services to be performed by
                               Lynx in Year 1.

               Year 2 ("Year 2"; [*]): [*] Dollars (USD $[*]), payable as [*]
                      payments of [*] Dollars (USD $[*]) [*] due on or before
                      the [*] day of [*] and [*], for the Services to be
                      performed by Lynx in Year 2.

               Year 3 ("Year 3"; [*]): [*] Dollars (USD $[*]), payable as [*]
                      payments of [*] Dollars (USD $[*]) [*] due on or before
                      the [*] day of [*] and [*], for the Services to be
                      performed by Lynx in Year 3.

               Year 4 ("Year 4"; [*]): [*] Dollars (USD $[*]), payable as [*]
                      payments of [*] Dollars (USD $[*]) [*]due on or before the
                      [*] day of [*] and [*], for the Services to be performed
                      by Lynx in Year 4.

               Year 5 ("Year 5"; [*]): [*] Dollars (USD $[*]), payable as [*]
                      payments of [*] Dollars (USD $[*]) [*] due on or before
                      the [*] day of [*] and [*], for the Services to be
                      performed by Lynx in Year 5.

      All amounts paid hereunder shall be made to Lynx in US Dollars by bank
      wire transfer to:

               [*]

5. Additional Technologies. The Parties agree that in any Year, Lynx Technology
      other than MPSS [*] shall be made available to DuPont for use under this
      Agreement. The Parties shall mutually determine the use and costs of any
      such technologies within that Year; however, such costs [*] DuPont for
      that Year.

6. Term and Termination. It is intended that the Services shall be provided, and
      this Agreement shall extend, for a period of five (5) years from the
      Effective Date, from [*], through [*] ("Term"),

                                  Page 4 of 12

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

<PAGE>

                                                             CONFIDENTIAL

      unless extended by mutual written consent of the Parties or earlier
      terminated ("Termination") through any of the following:

      a. By mutual agreement of the Parties in writing at any time;

      b. By DuPont after [*] from the Effective Date, upon [*] written notice to
         Lynx;

      c. By either Party upon [*] written notice, in the event the other Party
         commits a material breach of this Agreement, with such breach not
         corrected by the breaching Party within the [*] period;

      d. By DuPont upon [*] notice in the event that Lynx is unable to perform
         its obligations for the Services, to the reasonable satisfaction of
         DuPont, according to the milestones and specifications in the Work
         Plan; or

      e. By either Party at a moment's notice in the event the other Party (i)
         becomes insolvent or unable to pay its debts as they mature; (ii) makes
         an assignment for the benefit of creditors; (iii) permits or procures
         the appointment of a receiver for its assets; (iv) becomes the subject
         of any bankruptcy, insolvency, or similar proceeding; or (v) is
         acquired by or merged with another Party.

      In the event of Termination prior to completion of the Services for
      Analyses requested and paid by DuPont in advance of Termination, Lynx
      agrees that it will complete all such Services that have been paid for by
      DuPont, and deliver to DuPont all Results for Services that have been paid
      for, and return or destroy, at DuPont's discretion, all Samples remaining
      at Lynx at Termination.

7. Effects of Termination. All payment for completed Services rendered up to and
      including the last day of the Term, prior to expiration or Termination,
      shall remain due and payable to Lynx, and payment for partially completed
      Services at the time of Termination as described in Section 5 herein,
      shall be determined in good faith. Notwithstanding anything to the
      contrary in this Agreement, DuPont shall have no obligation to pay for any
      [*] of a [*] in which either Party terminates this Agreement, beyond the
      [*] containing the date of notice of Termination.

      Expiration or Termination of this Agreement shall not relieve Lynx of any
      obligation with respect to DuPont Confidential Information or Samples
      disclosed or Results developed prior to such expiration or Termination and
      shall not modify DuPont's ownership or use rights in DuPont Confidential
      Information, Samples or Results.

      In the event of [*], DuPont and its Affiliates have the right, at their
      sole option, to [*], the terms and conditions of such to be negotiated in
      good faith by the Parties at the date of exercise of such right.

8. Relationship of Parties. Both Parties agree that in the performance of this
      Agreement, Lynx is an independent contractor and neither Lynx nor any of
      its employees or agents will be an agent or employee of DuPont or its
      Affiliates or be covered by DuPont's or its Affiliates' Worker's
      Compensation Insurance or Unemployment Insurance. Further, neither Lynx
      nor any of its

                                  Page 5 of 12

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

<PAGE>

                                                             CONFIDENTIAL

      employees or agents will be eligible to participate in DuPont's or its
      Affiliates' retirement programs or be entitled to any other benefits from
      DuPont or its Affiliates.

9. Property and Use Rights.

      a. Copyright. DuPont and Lynx agree that any copyrightable work(s)
         developed in the performance of Services under this Agreement
         constitute work(s) made for hire under the United States Copyright Laws
         and that all right, title, and interests therein, including copyright,
         shall vest in DuPont. In the event that any such work does not qualify
         as a work made for hire under the United States Copyright laws, or for
         any other reason does not constitute a work made for hire, Lynx by this
         Agreement hereby assigns all right, title, and interest, including
         copyright, in said work(s) to DuPont, in perpetuity.

      b. Existing technology. Lynx represents and warrants that it either owns
         or has the right to use any technology or Intellectual Property used to
         carry out the Services under this Agreement, and further represents and
         warrants that neither Lynx Intellectual Property nor any existing or
         future Lynx contractual obligation outside this Agreement shall prevent
         DuPont from using the Results.

      c. Results. DuPont, including its Affiliates, shall be the exclusive owner
         of all right, title and interest in and to the Samples and Results
         resulting from provision of Services under this Agreement. DuPont shall
         have exclusive ownership and use rights to all discoveries, inventions
         and property, that are not directly related to Lynx Technology, arising
         from Results ("Developments"). Lynx shall irrevocably and perpetually
         assign, transfer and convey to DuPont all of Lynx's right, title and
         interest, if any, in and to all Results produced hereunder and to all
         Developments. Further, Lynx shall not disclose, transfer, sell, or use
         Results to, or use Results with or on behalf of, any third party.
         DuPont shall assume all responsibility for all costs associated with
         the application, prosecution, maintenance, defense and enforcement of
         patent applications and patents claiming all or a portion of the
         Samples and Results.

      d. Notwithstanding any other provision of this Agreement, and for the
         avoidance of doubt, DuPont and its Affiliates shall have the right to
         use and disclose Results, without exception, for any purpose
         whatsoever, without further consideration to Lynx.

      e. Lynx or its successors of interest shall not assert against DuPont and
         its Affiliates, business partners, agents or customers of each, any
         patent owned or controlled by Lynx that would prevent DuPont and its
         Affiliates, business partners, agents or customers from making, having
         made, using and selling products that were developed from Results.

      f. No right or license, either expressed or implied, is granted to Lynx
         under any material, information, patent, patent application, or
         trademark existing now or in the future.

                                  Page 6 of 12

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

<PAGE>

                                                             CONFIDENTIAL

10. Project Champions (PC's). A Project Champion ("PC") shall be designated by
      each of the Parties, which shall be [*] representative from each Party,
      each of whom shall be experienced in a relevant aspect of the Services
      and/or Samples. These representatives are named in the Schedule. The PC's
      shall coordinate and manage the aspects of the Services hereunder,
      including conducting [*] meetings at mutually convenient times and
      locations, to:

      a.    encourage and facilitate ongoing cooperation and information
            exchange between the Parties as necessary for the performance of
            each Party's obligations hereunder;

      b.    plan and agree upon a timetable for the Samples to be submitted and
            the Analyses to be conducted in [*];

      c.    evaluate data and results of work under Section 1 of this Agreement
            and to make recommendations to the Parties for changes in thereto,
            if necessary, to further the objectives of, and to [*] under, the
            Agreement;

      The PC's shall have no power to amend this Agreement and shall have only
      such powers as are specifically delegated to it hereunder.

11. Indemnification. Each Party agrees to defend, indemnify and hold the other
      Party (including its officers, employees and agents) harmless from and
      against any and all liability, loss, expense, reasonable attorneys' fees,
      or claims for injury or damages arising from the performance of this
      Agreement, but only in proportion to and to the extent such liability,
      loss, expense, reasonable attorneys' fees, or claims for injury or damages
      are caused by or result from the negligent or intentional acts or
      omissions of the indemnifying Party, its officers, agents or employees.

12. Disclaimer; Waiver

      LYNX MAKES NO REPRESENTATION OR EXPRESS OR IMPLIED WARRANTY THAT THE
      RESULTS OBTAINED FROM USE OF THE SAMPLES WILL NOT INFRINGE INTELLECTUAL
      PROPERTY RIGHTS OF THIRD PARTIES AND HEREBY DISCLAIMS THE SAME. DuPont
      WILL ACCEPT THE RESULTS WITH THE KNOWLEDGE THAT THEY ARE EXPERIMENAL IN
      NATURE. BECAUSE THE RESULTS ARE EXPERIMENTAL IN NATURE, THEY ARE BEING
      SUPPLIED TO DuPont WITH NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY
      WARRANTY OF MERHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.

13. Confidential Information. "Confidential Information" shall mean any and all
      information, know-how and data, technical or non-technical, disclosed or
      provided by one Party (the "Disclosing Party") to the other Party (the
      "Receiving Party") for or about the Services hereunder, whether disclosed
      or provided in oral, written, graphic, photographic, electronic, or any
      other form. Confidential Information of DuPont shall include Samples. Each
      party shall use its best efforts, consistent with its established policies
      and procedures, to protect the confidentiality of the other Party's
      Confidential Information. . This Agreement applies to all confidential
      information (including the terms of this Agreement) except to the extent
      that the Confidential Information:

                                  Page 7 of 12

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

<PAGE>

                                                             CONFIDENTIAL

      a.    Was part of the public domain at the time of disclosure;

      b.    Became part of the public domain by publication or otherwise, except
            by breach of this Agreement;

      c.    Can be established to have been in the possession of Receiving Party
            at the time of disclosure and was not acquired directly or
            indirectly from the Disclosing Party under a confidentiality
            obligation;

      d.    Was received from a third party without any restrictions; provided
            that the information was not obtained by that third party, directly
            or indirectly, in breach of a confidentiality obligation; or

      e.    Can be established to have been developed by Receiving Party
            independently of any disclosure by Disclosing Party.

      If a Disclosing Party requests protection to protect its Confidential
      Information by means not normally employed by the Receiving Party to
      protect its own confidential information, Disclosing Party agrees to
      reimburse Receiving Party in full for any costs it may incur in order to
      do so, which costs shall be pre-approved by the Disclosing Party. Further,
      should the Receiving Party be required by judicial or other governmental
      authority to disclose the Disclosing Party's Confidential Information, the
      Receiving Party shall immediately inform and cooperate with the Disclosing
      Party in responding to such requirement in a manner that maintains the
      confidentiality of the information to the maximum extent possible.

      Without limiting the foregoing, each Party will take at least those
      measures to protect the other Party's Confidential Information that it
      takes to protect its own confidential information of a similar nature.
      Each Party agrees to immediately notify the other Party should it become
      aware of any unauthorized use or disclosure of Confidential Information.

      The Receiving Party may disclose the Disclosing Party's Confidential
      Information only to the Receiving Party's and its Affiliates' employees,
      consultants, or licensees who (a) have a need-to-know in order to perform
      or satisfy its obligations under this Agreement and (b) are under
      obligation not to disclose or use Confidential Information, except as
      otherwise provided in this Agreement.

14. Notice. Any notice required or permitted hereunder shall be sent to the
      parties via U.S. Mail, postage prepaid, or by personal service, facsimile
      or as may otherwise be permitted by law, at the following addresses:

                  DuPont:                             LYNX:

      E.I. du Pont de Nemours and Co.         Lynx Therapeutics, Inc.
      Crop Genetics Research                  25861 Industrial Blvd.
      DuPont Experimental Station             Hayward, CA 94545
      Rt. 141 at Henry Clay Rd.               USA
      Wilmington, DE 19880-0402 USA

                                  Page 8 of 12

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

<PAGE>

                                                             CONFIDENTIAL

      [*]                          [*]

      Either party may change its address by written notice to the other during
      the term. All notices relating to this Agreement shall be in writing and
      shall be effective upon receipt.

15. Further Actions. The Parties agree to promptly execute, acknowledge and
      deliver such further instruments, and to do all such other acts, as the
      Parties agree are necessary or appropriate in order to carry out the
      purposes and intent of this Agreement.

16. Governing Law. This Agreement shall be construed in accordance with the laws
      of the State of California, without regard to its conflicts of laws
      principles.

17. Assignment. This Agreement shall not be assignable or otherwise transferable
      by either Party without the consent of the other Party, except that DuPont
      may, without such consent, assign this Agreement to any purchaser of all
      or substantially all of the assets in the line of business to which this
      Agreement pertains, or to any successor corporation that results from
      reincorporation, merger or consolidation of such Party with or into such
      purchaser or such corporation and DuPont may assign this Agreement to
      Affiliates. Upon assignment, the rights and obligations under this
      Agreement shall be binding upon and inure to the benefit of said purchaser
      or successor in interest.

18. Publicity and Use of Names. Lynx and DuPont shall not to use the other's
      name or trademarks in any advertising, publicity, or news release related
      to this Agreement and its subject matter without the prior written consent
      of the other Party.

19. Integrated Agreement, Amendment. This Agreement contains all the terms
      agreed upon by both Parties and may not be amended except in writing and
      signed by both Parties. The terms of this Agreement shall govern, in the
      case of conflict, over terms contained in the Work Plan or any form
      document including, but not limited to, quotes, invoices or proposals. The
      1998 Collaboration Agreement is terminated as of the Effective Date of
      this instant Agreement, and all work, results, inventions, rights, and
      obligations arising under or covered by the 1998 Collaboration Agreement
      are hereby governed by the terms and conditions of this instant Agreement.

20. Counterparts. This Agreement may be executed in counterparts and by
      facsimile signature, which shall together constitute one and the same
      agreement.

                                  Page 9 of 12

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

<PAGE>

                                                             CONFIDENTIAL

         IN WITNESS WHEREOF, the Parties have caused this Agreement to be
executed by their duly authorized representatives, as of the dates set forth
below.

E.I. DU PONT DE NEMOURS AND COMPANY                 LYNX THERAPEUTICS, INC.

By:   /s/ James E. Miller                        By: /s/ Kevin Corcoran
      ------------------------------------           ---------------------------

Name: James E. Miller                            Name:      Kevin Corcoran

Title: VP Crop Genetics Research & Development   Title:     President and CEO

Date: [*] 2003                                   Taxpayer ID # [*]
                                                                   -------------

                                                 Date: [*] 2003

                                 Page 10 of 12

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

<PAGE>

                                                             CONFIDENTIAL

                             SCHEDULE A : Work Plan

      Summary and Objective: This Work Plan describes the Samples, Analyses and
      Results for the DuPont Services in [*]. The corresponding information for
      the Services to be conducted in each subsequent Year during the Term of
      the Agreement will be discussed by the Parties by [*] of the previous [*],
      and each [*] Services description shall be appended to the Agreement.

      1. Samples

         The Samples will represent [*].

      2. The Project Champions (PCs) will be the following representatives:

         For DuPont/Pioneer: [*]
         For Lynx: [*]

      3. Description of Services

         In [*], Lynx will perform [*] MPSS [*] Analyses on DuPont/Pioneer's
         Samples. For these MPSS [*] Analyses:

      a) Lynx will perform the following quality control analysis on the
         DuPont/Pioneer Samples:

            [*]

      b) MPSS Process Overview:

         [*]

      c) [*]. Lynx may make [*] technology, [*]

      d) Dataset-Information (Results) to be provided to DuPont/Pioneer:

         For each [*] Sample provided by DuPont/Pioneer and analyzed by MPSS(TM)
         [*] process, Lynx will provide DuPont/Pioneer with the following [*]

            [*]

      3. [*]

                                 Page 11 of 12

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

<PAGE>

                                                             CONFIDENTIAL

      5. [*] Services

      For [*], DuPont/Pioneer and Lynx will meet in the [*] of the previous [*]
      to discuss and generate a mutual plan for the subject upcoming [*], and to
      generate a corresponding description of the upcoming [*] Services[*]:

          [*]

                                 Page 12 of 12

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00058-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00058-of-00352.parquet"}]]